Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374420 | 0.87 | CASR (0.67) | SMN1; SMN2KMT2AMEN1MAPTCASR | |
| SCHEMBL7833515 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1MAPTLMNA | |
| SCHEMBL7335938 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1MAPTLMNA | |
| SCHEMBL19334378 | 0.85 | MEN1 (0.44) | SMN1; SMN2KMT2AMEN1MAPTCASR | |
| SCHEMBL710603 | 0.84 | LMNA (0.57) | SMN1; SMN2KMT2AMEN1MAPTLMNA | |
| SCHEMBL8763565 | 0.84 | CASR (0.60) | SMN1; SMN2KMT2AMEN1MAPTCASR | |
| SCHEMBL14574199 | 0.83 | MEN1 (0.56) | SMN1; SMN2KMT2AMEN1MAPTCASR | |
| SCHEMBL11073849 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2AMEN1MAPTCASR | |
| Acetone SCHEMBL28637824 | 0.81 | TP53 (0.58) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL11582892 | 0.81 | MEN1 (0.70) | SMN1; SMN2KMT2AMEN1MAPTCASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0647135-A4 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY. | CANCER SOC AUCKLAND DIV NZ INC (NZ) | 1995-07-05 | — | — | EP | claimed |
| EP-0647135-A1 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) | 1995-04-12 | — | — | EP | claimed |
| WO-1994000115-A1 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) | 1994-01-06 | — | — | WO | claimed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-0647135-A4 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY. | CANCER SOC AUCKLAND DIV NZ INC (NZ) | 1995-07-05 | — | — | EP | disclosed |
| EP-0647135-A1 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) | 1995-04-12 | — | — | EP | disclosed |
| US-5331004-A | Anticancer agents, crosslinking DNA | CIRCADIAN PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (AU) | 1994-07-19 | — | — | US | disclosed |
| WO-1994000115-A1 | BIS-(SUBSTITUTED-PHENYL) DERIVATIVES WITH CYTOTOXIC AND ANTICANCER ACTIVITY | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | SMN1; SMN2 3631/4885KMT2A 2502/4885MEN1 2868/4885 |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | SMN1; SMN2 3912/4885KMT2A 1608/4885MEN1 2792/4885 |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | SMN1; SMN2 3912/4885KMT2A 1608/4885MEN1 2792/4885 |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | LIG1, LIG4, LIG3 | SMN1; SMN2 3912/4885KMT2A 1608/4885MEN1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.